miRNA Expression: I/R Cardiomyocyte and Sevoflurane

Area of Science:

• Cardiology
• Anesthesiology
• Molecular Biology

Background:

• Anesthetic drugs, particularly sevoflurane, offer clinical benefits in cardiac surgery.
• These benefits involve molecular pathways mediated by microRNAs (miRNAs).
• The impact of anesthetics on miRNA expression and cardioprotection remains unclear.

Purpose of the Study:

• To investigate how halogenated anesthetics alter miRNA expression.
• To identify specific miRNAs responsible for the cardioprotective effects of sevoflurane.
• To analyze variations in miRNA expression induced by sevoflurane and propofol.

Main Methods:

• An in vitro ischemia/reperfusion (I/R) model using human cardiac myocytes (HCMs).
• Comparison of four groups: control, I/R, I/R with propofol (I/R-P), and I/R with sevoflurane (I/R-S).
• Quantification of p53 and Akt1 cytokines and miRNA profiling via Next Generation Sequencing (NGS).

Main Results:

• Sevoflurane exposure in I/R HCMs led to lower p53 and higher Akt-1 levels compared to propofol.
• NGS revealed significantly increased expression of hsa-miR-140-5p, hsa-miR-455-5p, hsa-miR-98-5p, hsa-miR-193a-5p, and hsa-let-7d-5p in the sevoflurane group.
• These upregulated miRNAs are associated with cardiac function, apoptosis inhibition, and myocardial protection.

Conclusions:

• Sevoflurane induces overexpression of specific miRNAs, conferring cardioprotection.
• These miRNA changes occur at DNA and signaling pathway levels, including Akt/ERK.
• The findings highlight sevoflurane's potential for myocardial protection through miRNA modulation.